[Latin Name] Griffonia simplicifolia

[Plant Source] Griffonia Seed

[Specifications] 98%; 99% HPLC

[Appearance] White fine powder

Plant Part Used: Seed

[Particle size] 80 Mesh

[Loss on drying] ≤5.0%

[Heavy Metal] ≤10PPM

[Pesticide residue] EC396-2005, USP 34, EP 8.0, FDA

[Storage] Store in cool & dry area, keep away from the direct light and heat.

[Shelf life] 24 Months

[Package] Packed in paper-drums and two plastic-bags inside.

[Net weight] 25kgs/drum

[What is 5-HTP]

5-HTP (5-Hydroxytryptophan) is a chemical by-product of the protein building block L-tryptophan. It is also produced commercially from the seeds of an African plant known as Griffonia simplicifolia 5-HTP is used for sleep disorders such as insomnia, depression, anxiety, migraine and tension-type headaches, fibromyalgia, obesity, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), attention deficit-hyperactivity disorder (ADHD), seizure disorder, and Parkinson’s disease.

 [How does it work?]

5-HTP works in the brain and central nervous system by increasing the production of the chemical serotonin. Serotonin can affect sleep, appetite, temperature, sexual behavior, and pain sensation. Since 5-HTP increases the synthesis of serotonin, it is used for several diseases where serotonin is believed to play an important role including depression, insomnia, obesity, and many other conditions.

[Function]

Depression. Some clinical research shows that taking 5-HTP by mouth improve symptoms of depression in some people. Some clinical research shows that taking 5-HTP by mouth might be as beneficial as certain prescription antidepressant drugs for improving depression symptoms. In most studies, 150-800 mg daily of 5-HTP was taken. In some cases, higher doses have been used.

Down syndrome. Some research shows that giving 5-HTP to infants with Down syndrome might improve muscle and activity. Other research shows that it does not improve muscle or development when taken from infancy until 3-4 years of age. Research also shows that taking 5-HTP along with conventional prescription drugs does improve development, social skills, or language skills.

Anxiety 5-HTP was found to be protective against carbon dioxide-induced panic attacks. One study compared 5-HTP and the prescription medication clomipramine for anxiety. Clomipramine is a tricyclic antidepressant used for treating obsessive-compulsive disorder. 5-HTP was found to be somewhat effective in reducing anxiety symptoms, but not as effective as clomipramine.

Sleep 5-HTP supplements fared a little better for insomnia.5-HTP decreased the time required to get to sleep and decreased the number of nighttime awakenings. Taking 5-HTP along with GABA (gamma-aminobutyric acid), a relaxing neurotransmitter, reduced the time it took to fall asleep and increased the duration and quality of sleep. One study found that children with night terrors benefited from 5-HTP.

Jose S. Pulido, M.D., Professor of Opthalmology & Molecular Medicine, Mayo Clinic College of Medicine and Alan D. Marmorstein, Ph.D., Professor of Ophthalmology, Mayo Clinic College of Medicine discuss the importance of genetic testing in diagnosing macular degeneration. Three cases are outlined that have been referred to as Adult Onset Foveomacular Dystrophy, Macular Degeneration, and Best Disease. Genetic testing can be used to make these diagnoses and researchers are at the threshold of new and exciting treatments. Over the past few years Dr. Marmorstein’s laboratory has been involved in a study of stem cell models of Best Disease and other retinal degenerative diseases. Details can be found on the NIH web site. DNA is being collected along with skin fibroblasts from patients with Best Disease Adult Vitelliform Dystrophy Autosomal Recessive Bestrophinopathy, autosomal dominant vitreoretinal choroidopathy, and retinitis pigmentosa due to mutations in BEST1. The skin fibroblasts are being reprogrammed into induced pluripotent stem cells which can be differentiated into retinal pigment epithelial cells. This is the cell where Bestrophin, the product of the BEST1 gene is expressed and that’s where the pathogenic problem that results in these diseases occurs. Clinical trials are already underway using iPS cell derived retinal pigment epithelial cells for the treatment of age-related Macular Degeneration. It also allows the consideration of the same process to therapeutically treat Best Disease and Adult Vitelliform Macular Dystrophy, Autosomal Recessive Bestrophinopathy and models of the diseases can be generated of the diseases in the laboratory. This can help with the understanding of the processes that cause the disease and allow for the testing of potential therapeutic compounds to determine if they have an effect on these specific patients.

For more information, visit: https://www.mayoclinic.org/departments-centers/ophthalmology?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=video&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504